On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer.
暂无分享,去创建一个
Scott D Ramsey | S. Ramsey | D. Penson | D. Ekwueme | S. Zeliadt | David F Penson | I. Hall | Ingrid J Hall | Donatus U Ekwueme | Steven B Zeliadt
[1] H M Sandler,et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.
[2] M. Barry,et al. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000. , 2004, Journal of the National Cancer Institute. Monographs.
[3] D. Lubeck,et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. , 1999, Urology.
[4] J Kievit,et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] B. Given,et al. Physical Functioning and Depression Among Older Persons with Cancer , 2001 .
[6] D. Lubeck,et al. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. , 2001, The Journal of urology.
[7] J. Coebergh,et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. , 1999, Journal of clinical epidemiology.
[8] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[9] E. Klein,et al. Sexuality and Health-Related Quality of Life After Prostate Cancer in African-American and White Men Treated for Localized Disease , 2004, Journal of sex & marital therapy.
[10] John T. Wei,et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. , 2004, The Journal of urology.
[11] J. Johansson,et al. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. , 1998, Urology.
[12] K. Armstrong,et al. Development and testing of the health care system distrust scale , 2007, Journal of General Internal Medicine.
[13] S. Madersbacher,et al. Frequent use of complementary medicine by prostate cancer patients. , 2003, European urology.
[14] John T. Wei,et al. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. , 2003, The Journal of urology.
[15] H. D. de Koning,et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Lubeck,et al. Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. , 2002, The Journal of urology.
[17] Ruth Etzioni,et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. , 2004, Urology.
[18] G. Naglie,et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. , 2005, Journal of the National Cancer Institute.
[19] E. Giovannucci,et al. The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patients , 2002, Cancer.
[20] D. Kuban,et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. , 2001, The Journal of urology.
[21] S H Kaplan,et al. Development and testing of a new measure of case mix for use in office practice. , 1995, Medical care.
[22] C. Ashton,et al. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Helgeson,et al. Early quality of life in patients with localized prostate carcinoma , 2001, Cancer.
[24] J. Stanford,et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.
[25] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[26] W. Catalona,et al. Quality‐of‐life outcomes for men with prostate carcinoma detected by screening , 2000, Cancer.
[27] R A Stephenson,et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.
[28] R. Heinrich,et al. Development of a comprehensive quality of life measurement tool: CARES. , 1990, Oncology.
[29] A. Zwinderman,et al. A Prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients , 2004, The Prostate.
[30] P. F. Short,et al. Income Disparities in the Quality of Life of Cancer Survivors , 2006, Medical care.
[31] Srinivasan Vijayakumar,et al. Prostate cancer, race, and socioeconomic status: Inadequate adjustment for social factors in assessing racial differences , 1996, The Prostate.
[32] K. Yoshimura,et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer , 2003, International journal of urology : official journal of the Japanese Urological Association.
[33] Per Carlsson,et al. The estimated economic value of the welfare loss due to prostate cancer pain in a defined population , 2004, Acta oncologica.
[34] R H Brook,et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.
[35] O. Brawley,et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Coebergh,et al. Quality of life among long-term breast cancer survivors: a systematic review. , 2005, European journal of cancer.
[37] I. Thompson,et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. , 2001, Journal of the National Cancer Institute.
[38] F. Meyers,et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D. Lubeck,et al. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. , 2001, Journal of clinical epidemiology.
[40] P Carlsson,et al. A population-based study of pain and quality of life during the year before death in men with prostate cancer , 2004, British Journal of Cancer.
[41] W. Catalona,et al. Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. , 1999, The Journal of urology.
[42] P. Iyer,et al. Comparative study of the clinical efficacy of two dosing regimens of flutamide. , 1999, Molecular urology.
[43] M. Litwin,et al. Health-Related Quality-of-Life in Low-Income, Uninsured Men with Prostate Cancer , 2005, Journal of health care for the poor and underserved.
[44] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[45] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[46] V. Shavers,et al. Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.
[47] T. Tammela,et al. A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.
[48] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.